An extension of the model free test to test synergy in multiple drug combinations

Biometrical Journal

Volumn 46, Issue 3, 2004, Pages 293-304

  Feng, Ping ^a   Kelly, Colleen ^b  

^a SICHUAN UNIVERSITY   (China)

^b SAN DIEGO STATE UNIVERSITY   (United States)

Author keywords

Additivity; Dose response; Drug interactions; Synergy

Indexed keywords

DRUG DOSAGE; SURFACE PROPERTIES;

ADDITIVITY; CURVE METHOD; DOSE RESPONSE; DOSE-RESPONSE CURVES; DRUG COMBINATIONS; ENVIRONMENTAL STUDIES; MODEL FREE; POWER; STATISTICAL APPROACH; SYNERGY;

DRUG INTERACTIONS;

EID: 22144458885     PISSN: 03233847     EISSN: None     Source Type: Journal    
DOI: 10.1002/bimj.200310038     Document Type: Article

References (32)

1. Berenbaum, M. C. (1985). The expected effect of a combination of agents: the general solution. Journal of Theoretical Biology 114, 413-431.
2. Berenbaum, M. C. (1989). What is synergy? Pharmacology Reviews 41, 93-141.
3. Carter, W. H., Jr., Chinchilli, V. M., Wilson, J. D., Campbell, E. D., Kessler, F. K. and Carchman, R. A. (1986). An asymptotic confidence region for the ED100p from the logistic response surface for a combination of agents. American Statistician 40, 124-128.
4. Carter, W. H., Jr., Gennings, C., Staniswalis, J. G., Campbell, E. D. and White, K. L., Jr. (1988). A statistical approach to the construction and analysis of isobolograms. Journal of American College of Toxicology 7, 963-973.
5. nd edition, Duxbury Thomson Learning, Pacific Grove, CA.
6. Collen, D. (1988). Synergism of thrombolytic agents: Investigational procedures and clinical potential. Circulation 77, 731-735.
7. Collen, D., Stump, D. C. and Van Der Werf, F. (1986). Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. American Heart Journal 112, 1083-1084.
8. Collen, D. and Van Der Werf, F. (1987). Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. American Journal of Cardiology 60, 431-434.
9. Gazitt, Y., Rothenberg, M. L., Hilsenbeck, S. G., Fey, V, Thomas, C. and Montegomrey, W. (1998). Bcl-2 over-expression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells. International Journal of Oncology 13, 839-848.
10. Gennings, C. (1995). An efficient experimental design for the detecting departure from additivity in mixtures of many chemicals. Toxicology 105, 189-197.
11. Greco, W. R., Park, H. S. and Rustum, Y. M. (1990). An application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-B-D-arabinofuranosylcytosine. Cancer Research 50, 5318-5327.
12. Greco, W. R., Bravo, G. and Parson, J. C. (1995). The search for synergy: A critical review from a response surface perspective. Pharmacological Reviews 47, 331-383.
13. Kawashima, T. (2003). Analysis of drug combination: comparing the marginal dose-response curve method and the model-free test method. Master's Degree Thesis, San Diego CA, 92182.
14. Kelly, C., T. Kawashima and P. Feng (2003). An improved Model-Free Test of synergy in drug combinations. 2003 Proceedings of the American Statistical Association, Biometrics Section [CD-ROM], San Francisco, CA, American Statistical Association.
15. Kelly, C. and Rice, J. (1990). Monotone soothing with application to dose-response curves and the assessment of synergism. Biometrics 46, 1071-1085.
16. Laska, E. M. and Meisner, M. J. (1989). Testing whether an identified treatment is best. Biometrics 45, 1139-1151.
17. Laska, E. M., Meisner, M. and Seigel, C. (1994). Simple designs and model-free tests for synergy. Biometrics 50, 834-841.
18. Loewe, S. and Muischnek, H. (1926). Effect of combinations: mathematical basis of problem. Archiv für Experimentelle Pathologie und Pharmakologie 114, 313-326.
19. McDougal A., Wormke, M., Calvin, J. and Sate, S. (2001). Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Research 61, 3902-3907.
20. Moser, M. (1989). Relative efficacy of, and some adverse reactions to, different antihypertensive regimens. American Journal of Cardiology 63, 2B-7B
21. Patel, H. I. (1991). Comparison of treatments in a combination therapy trial. Journal of Biopharmaceutical Statistics 1, 171-183.
22. Plummer, J. L., Cmielewski, P. L., Gourlay, G. K., Owen, H. and Cousins, M. J. (1992). Antinociceptive and motor effects of intrathecal morphine combined with intrathecal clonidine noradrenaline, carbachol or midasolam. Pain 49, 145-152.
23. Plummer, J. L. and Gourlay, G. K. (1992). Letters to the Editor: Reply to the letter of Dr. Gebhart. Pain 51, 387-388.
24. Rahimtoola, S. H. (1989). The pharmacologic treatment of chronic congestive heart failure. Circulation 80, 693-699.
25. Sarkar, S. K., Snapinn, S. and Wang, W. (1993). On improving the min test for the analysis of combination drug trials. ASA Proceedings of the Biopharmaceutical Section, 212-217.
26. Sethna, N. F., Liu, M., Gracely, R., Bennett, G. J. and Max, M. B. (1998). Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesthesia Analgesia 86, 1250-1256.
27. Simone, J. V. (1979). Childhood leukemia as a model for cancer research. Cancer Research 39, 4301-4307.
28. Slapak, M. (1987). Triple and quadruple immunosuppressive therapy in organ transplantation. Lancet 2, 958-960.
29. Snapinn, S. M. (1987). Evaluating the efficacy of a combination therapy. Statistics in Medicine 6, 657-665.
30. S-plus (2000): MathSoft, Inc. Seattle.
31. Weitman, S., Barrera, H., Moore, R., Gonzalez, C., Marty, J., Hilsenbeck, S., MacDonald, J. R., Waters, S. J. and Hoff, D. V. (2000). Augmentation of antitumor activity when combined with topotecan. Journal of Pediatric Hematology/Oncology 22, 306-314.
32. 3, and sodium butyrate on differentiation in HL-60 cells. Oncology Research 12, 419-427.